Gain Therapeutics (NASDAQ:GANX) Research Coverage Started at Scotiabank

Scotiabank started coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research note released on Friday morning, MarketBeat.com reports. The firm issued a sector outperform rating and a $12.00 price objective on the stock.

Several other research firms have also weighed in on GANX. Roth Mkm reiterated a “buy” rating and set a $7.00 target price on shares of Gain Therapeutics in a research note on Tuesday, December 24th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, November 25th. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Up 4.4 %

GANX stock opened at $1.88 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a 1-year low of $0.89 and a 1-year high of $4.80. The firm has a fifty day moving average price of $2.25 and a two-hundred day moving average price of $1.96. The firm has a market cap of $49.87 million, a price-to-earnings ratio of -1.71 and a beta of 0.14.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently bought and sold shares of GANX. Sprott Inc. acquired a new stake in Gain Therapeutics in the fourth quarter worth about $30,000. Benedict Financial Advisors Inc. bought a new stake in Gain Therapeutics in the fourth quarter worth about $35,000. Bridgeway Capital Management LLC bought a new stake in Gain Therapeutics in the fourth quarter worth about $65,000. Northern Trust Corp raised its position in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares in the last quarter. Finally, Marshall Wace LLP bought a new stake in Gain Therapeutics in the fourth quarter worth about $198,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.